Health ❯Pharmaceuticals ❯Clinical Trials
Drug Development TAMARACK Study Botensilimab and Balstilimab
Five-year trial results show unprecedented survival rates and reduced brain metastasis in ALK-positive non-small cell lung cancer patients.
